News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Amgen (AMGN), Allergan (AGN) Make History With First Cancer Biosimilar OK—Will Take on Genentech (RHHBY)'s $6 Billion Best-Seller     9/18/2017
Bristol-Myers Squibb (BMY)'s Stock Topples as Kidney Cancer Drug Flunks Phase III Study     8/16/2017
Cerulean (CERU) Shares Decimated as Renal Cell Carcinoma Drug Comes Up Short in Mid-Stage Study     8/18/2016
Pfizer (PFE) Stock Climbs With Positive Renal Cancer Phase III Data     7/8/2016
Mologen (MOLGF.PK) Restructures, Pushes Immunology Program, Shelves Renal Cancer Vaccine     6/9/2016
Exelixis (EXEL)' Cabozantinib Met Primary Endpoint in Phase II Renal Cell Carcinoma Study     5/23/2016
Exelixis (EXEL)'s Cabozantinib Shines in Late Stage Study for Patients with Advanced RCC     1/6/2016
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe     12/21/2015
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo     9/16/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib     8/25/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News     7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study     7/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014

News from Around the Web

Press Releases
Argos (ARGS) Reports On Interim Analysis Of Phase III ADAPT Trial Presented At ESMO 2017 Congress     9/12/2017
Bristol-Myers Squibb (BMY)'s Drug Combo Wows, Cuts Kidney Cancer Death Risk By 37%     9/11/2017
Eisai Inc. (ESALF.PK) Release: Combination Of Lenvatinib And Pembrolizumab Results In Notable Response Rates For Patients With Advanced Renal Cell Carcinoma Based On Interim Analysis Of Ongoing Phase Ib/II Trial     9/11/2017
TRACON Pharma (TCON) Announces Completion Of Enrollment In Randomized Phase IIb TRAXAR Study Of TRC105 And Inlyta® In Renal Cell Carcinoma     9/7/2017
Bristol-Myers Squibb (BMY) Data At ESMO 2017 Demonstrate Company’s Innovative Research Approach To Treating Cancer From All Angles     8/31/2017
AVEO Oncology (AVEO) Announces FOTIVDA (Tivozanib) Approved In The European Union For The Treatment Of Advanced Renal Cell Carcinoma     8/28/2017
EUSA Pharma Release: FOTIVDA (Tivozanib) Now Licensed In The European Union For The First-Line Treatment Of Advanced Renal Cell Carcinoma     8/28/2017
Immunicum Completes Strategic Analysis And Defines Updated Clinical Development Plan For Ilixadencel     8/17/2017
Calithera Biosciences (CALA) Initiates A Randomized Phase II Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma     8/7/2017
AVEO Oncology (AVEO) Announces Positive CHMP Opinion For Tivozanib As A Treatment Of Advanced Renal Cell Carcinoma     6/26/2017
Immunicum Announces Publication In Journal For Immunotherapy Of Cancer Of Results Overview From Ilixadencel's First Clinical Study In Metastatic Renal Cell Carcinoma     6/20/2017
Calithera Biosciences (CALA) Announces FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma     6/7/2017
Corvus Pharma Announces Interim Results Demonstrating Anti-Tumor Activity Of CPI-444 In Renal And Lung Cancer Patients Resistant Or Refractory To Prior PD-(L)1 Treatment     6/5/2017
Xynomic Pharma And UCSF Entered Strategic Partnership In Conducting A Phase II/III Trial Of Abexinostat Against Renal Cell Carcinoma     5/22/2017
AVEO Oncology (AVEO) Announces Completion Of A CHMP Oral Explanation For Tivozanib As A Treatment Of First-Line Renal Cell Carcinoma     5/19/2017

//-->